非典型溶血性尿毒症综合征与C3肾小球病:KDIGO争议会议结论
2015年KDIGO争议会议汇集全球专家,讨论非典型溶血性尿毒症综合征(aHUS)与C3肾小球病(C3G)的肾脏病理、临床表型、遗传与获得性驱动因素及治疗策略,提出最佳治疗建议并识别知识缺口,提出优先研究议程。
要点
- aHUS与C3G的发病中补体均起主要作用。
- 会议讨论了肾脏病理、临床表型与评估、遗传及获得性驱动因素和治疗策略。
- 会议提出最佳治疗策略建议,识别知识缺口并拟定优先研究议程。
核心结论
- aHUS与C3G中补体在发病机制中起主要作用。
- 会议就最佳治疗策略提出建议,并识别知识缺口、提出优先研究议程以解决争议问题。
研究设计与样本
- 2015年KDIGO争议会议,由全球专家小组讨论aHUS与C3G管理的关键问题。
主要发现
- 会议讨论了肾脏病理、临床表型与评估、遗传驱动因素、获得性驱动因素及治疗策略。
- 会议就最佳治疗策略进行了详细讨论,并提供支持当前治疗选择的证据基础。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In both atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G) complement plays a primary role in disease pathogenesis. Herein we report the outcome of a 2015 Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference where key issues in the management of these 2 diseases were considered by a global panel of experts. Areas addressed included renal pathology, clinical phenotype and assessment, genetic drivers of disease, acquired drivers of disease, and treatment strategies. In order to help guide clinicians who are caring for such patients, recommendations for best treatment strategies were discussed at length, providing the evidence base underpinning current treatment options. Knowledge gaps were identified and a prioritized research agenda was proposed to resolve outstanding controversial issues.
引用
- Goodship TH, Cook HT, Fakhouri F, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int. 2016. PMID: 27989322. doi:10.1016/j.kint.2016.10.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。